|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003015,
umls-concept:C0010592,
umls-concept:C0019868,
umls-concept:C0022671,
umls-concept:C0032821,
umls-concept:C0332293,
umls-concept:C0376387,
umls-concept:C0441889,
umls-concept:C0455272,
umls-concept:C0521942,
umls-concept:C0857121,
umls-concept:C1280500,
umls-concept:C2347899
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2001-4-30
|
|
pubmed:abstractText |
The angiotensin II (AT II) type I receptor antagonist losartan has been reported to increase urinary uric acid and potassium excretion. These effects might be beneficial in cyclosporin (CsA)-treated renal transplant recipients, who frequently suffer from hyperuricaemia and hyperkalaemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Enalapril,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/Potassium,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Uric Acid
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0931-0509
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1034-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11328912-Aged,
pubmed-meshheading:11328912-Angiotensin Receptor Antagonists,
pubmed-meshheading:11328912-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:11328912-Antihypertensive Agents,
pubmed-meshheading:11328912-Blood Pressure,
pubmed-meshheading:11328912-Cross-Over Studies,
pubmed-meshheading:11328912-Cyclosporine,
pubmed-meshheading:11328912-Enalapril,
pubmed-meshheading:11328912-Female,
pubmed-meshheading:11328912-Homeostasis,
pubmed-meshheading:11328912-Humans,
pubmed-meshheading:11328912-Hypertension,
pubmed-meshheading:11328912-Immunosuppressive Agents,
pubmed-meshheading:11328912-Kidney Transplantation,
pubmed-meshheading:11328912-Losartan,
pubmed-meshheading:11328912-Male,
pubmed-meshheading:11328912-Middle Aged,
pubmed-meshheading:11328912-Potassium,
pubmed-meshheading:11328912-Prospective Studies,
pubmed-meshheading:11328912-Receptor, Angiotensin, Type 1,
pubmed-meshheading:11328912-Receptor, Angiotensin, Type 2,
pubmed-meshheading:11328912-Uric Acid
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
|
|
pubmed:affiliation |
Division of Nephrology and Dialysis, Department of Medicine III, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
